Abatacept in rheumatoid arthritis-associated interstitial lung disease: short-term outcomes and predictors of progression.
Marika TardellaMarco Di CarloMarina CarottiAndrea GiovagnoniFausto SalaffiPublished in: Clinical rheumatology (2021)
Treatment with ABA is associated with a RA-ILD stability or improvement in the 88.6% of patients. Current smoking habit and concomitant treatment with methotrexate are the modifiable factors associated with RA-ILD worsening. Key Points • Abatacept plays a favourable role in the control of RA-ILD, with a significant worsening in only 11.4% of patients during a 18-month follow-up period. • The predictive variables related to RA-ILD progression during abatacept therapy are the concomitant treatment with methotrexate and current smoking habit.
Keyphrases
- interstitial lung disease
- rheumatoid arthritis
- systemic sclerosis
- disease activity
- end stage renal disease
- idiopathic pulmonary fibrosis
- newly diagnosed
- ankylosing spondylitis
- ejection fraction
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- rheumatoid arthritis patients
- low dose
- stem cells
- mesenchymal stem cells
- patient reported
- drug induced